Promidis is a private owned company, part of the IRBM group, focused on the identification of innovative drugs in high unmet medical need areas, and on offering a highly competitive spectrum of drug discovery (DD) actvities. Promidis was established in 2013, within the IRBM Science Park in Pomezia (Rome), and then relocated in November 2015 to the San Raffaele Hospital Science Park (SRSI), in Milan. The current privileged location of Promidis, within the campus of an internationally recognized center of excellence of biomedical research, aims to create an innovative portfolio of DD projects joining the cutting-edge pre-clinical and clinical research activities occurring at the SRSI for a variety of relevant human diseases, and the proven experience of members of Promidis in DD.
The management team at Promidis is made by experienced “drug hunters” with recognized competence in DD, spanning from early DD to the identification of high quality clinical candidates – often converted into marketed drugs – in areas such as CNS, antiviral, oncology and infection diseases. Promidis currently employees ∼15 scientists (all qualified to MSc/PhD) with extensive synthetic chemistry and drug discovery experience from big Pharma and SMEs. Promidis operates a hybrid business model, having proprietary DD programs and offering, as partner research organization (PRO) in partnership with IRBM, integrated DD (rational drug design, HTS, HitID, H2L and LOP) and process chemistry activities (chemical route finding, scale-up process, detection and characterization of impurities).